| Autor: |
Ioannides, D., Antonakopoulos, N., Chasapi, V., Oikonomou, C., Tampouratzi, E., Lazaridou, E., Rigopoulos, D., Neofotistou, O., Drosos, A., Anastasiadis, G., Rovithi, E., Kalinou, C., Papadavid, E., Aronis, P., Papageorgiou, M., Protopapa, A., Bassukas, I., Lefaki, I., Zafiriou, E., Krasagakis, K. |
| Předmět: |
|
| Zdroj: |
Journal of the European Academy of Dermatology & Venereology; Nov2022, Vol. 36 Issue 11, p2055-2063, 9p |
| Abstrakt: |
Background: Real‐world data in patients with moderate psoriasis treated with apremilast is limited. Objectives: To evaluate the effectiveness and safety of apremilast in bio‐naïve patients with moderate psoriasis in real‐world clinical settings. Methods: This was a 52‐week multicenter, observational, prospective study of adult outpatients with moderate psoriasis {[10% < body surface area < 20% or 10 < psoriasis area severity index (PASI) < 20] and 10 < dermatology quality of life index (DLQI) < 20} initiated on apremilast ≤7 days before enrollment. Missing data were imputed using the last observation carried forward method. Results: A total of 287 eligible patients (median age: 54.2 years; median psoriasis duration: 9.8 years) were consecutively enrolled. At baseline, the median DLQI and PASI scores were 12.0 and 11.8, respectively. The 52‐week DLQI ≤ 5 and PASI75 response rates were 68.3% and 61.0%. At 52 weeks, 70.8% and 72.7% of the patients shifted from moderate/severe/very severe to clear/minimal scalp and palmoplantar psoriasis involvement, respectively; the pruritus severity state improved in 67.2%. The 52‐week Kaplan–Meier estimated drug continuation rate was 85.3%. The adverse drug reaction rate was 19.9%. Conclusions: Apremilast is a safe and effective treatment for bio‐naïve patients with moderate psoriasis and specific psoriasis manifestations. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text